Associated Papers
Pharmacogenetic Variants Associated with Fluoxetine Pharmacokinetics from a Bioequivalence Study in Healthy Subjects.
Díaz-Tufinio CA et al.
Journal of Personalized Medicine, 2023
Assessment of CYP2C9, CYP2C19, and CYP2D6 Polymorphisms in Allergic Patients with Chemical Sensitivity.
D'Attis S et al.
International Archives of Allergy and Immunology, 2019
Flexible and Scalable Full-Length CYP2D6 Long Amplicon PacBio Sequencing.
Buermans HP et al.
Human Mutation, 2017
28044414 (PubMed )
Supplement: HUMU-38-310-s004.xlsx › Sup_Table_3
CYP2D6 polymorphisms may predict occurrence of adverse effects to tamoxifen: a preliminary retrospective study.
Wickramage I et al.
Breast Cancer (dove Medical Press), 2017
Pharmacogenetic testing revisited: 5' nuclease real-time polymerase chain reaction test panels for genotyping CYP2D6 and CYP2C19.
Larsen JB et al.
Pharmacogenomics and Personalized Medicine, 2017
SNP genotyping using TaqMan technology: the CYP2D6*17 assay conundrum.
Gaedigk A et al.
Scientific Reports, 2015
Impact of physiological, pathological and environmental factors on the expression and activity of human cytochrome P450 2D6 and implications in precision medicine.
He ZX et al.
Drug Metabolism Reviews, 2015
Characterization of 107 genomic DNA reference materials for CYP2D6, CYP2C19, CYP2C9, VKORC1, and UGT1A1: a GeT-RM and Association for Molecular Pathology collaborative project.
Pratt VM et al.
The Journal of Molecular Diagnostics : Jmd, 2010
Elucidation of CYP2D6 genetic diversity in a unique African population: implications for the future application of pharmacogenetics in the Xhosa population.
Wright GE et al.
Annals of Human Genetics, 2010
Genotyping panel for assessing response to cancer chemotherapy.
Dai Z et al.
Bmc Medical Genomics, 2008
18547414 (PubMed )
Supplement: 1755-8794-1-24-S1.xls › SNPs_selected_for_SNPlex_design
Development of lung cancer before the age of 50: the role of xenobiotic metabolizing genes.
Gemignani F et al.
Carcinogenesis, 2007
A novel intronic mutation, 2988G>A, with high predictivity for impaired function of cytochrome P450 2D6 in white subjects.
Raimundo S et al.
Clinical Pharmacology and Therapeutics, 2004
Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry.
Zanger UM et al.
Naunyn-schmiedeberg's Archives of Pharmacology, 2004
Post-mortem SNP analysis of CYP2D6 gene reveals correlation between genotype and opioid drug (tramadol) metabolite ratios in blood.
Levo A et al.
Forensic Science International, 2003
Select a paper to view details